Contact
searchSearch
HMP Global

Nonradiographic Axial Spondyloarthritis

Featured Article

News
Bimekizumab Demonstrates Rapid and Sustained Efficacy in Treating NrxSpA, Regardless of Prior TNF Inhibitor Exposure
12/21/2023
Hannah Musick
A new monoclonal antibody, bimekizumab (BKZ), demonstrated promising results in improving efficacy outcomes for patients with axial spondyloarthritis (axSpA), even in those who have lost response to TNF inhibitors or are intolerant to them,...
A new monoclonal antibody, bimekizumab (BKZ), demonstrated promising results in improving efficacy outcomes for patients with axial spondyloarthritis (axSpA), even in those who have lost response to TNF inhibitors or are intolerant to them,...
A new monoclonal antibody,...
12/21/2023
First Report Managed Care
News
NrxSpA Classification Holds Little Relevance in Daily Practice
11/06/2023
Jolynn Tumolo
While the terms nonradiographic axial spondyloarthritis (NrxSpA) and radiographic axial spondyloarthritis (R-axSpA) may sometimes be helpful for stratifying patients with axial spondyloarthritis (axSpA) in clinical studies, the terms are less...
While the terms nonradiographic axial spondyloarthritis (NrxSpA) and radiographic axial spondyloarthritis (R-axSpA) may sometimes be helpful for stratifying patients with axial spondyloarthritis (axSpA) in clinical studies, the terms are less...
While the terms nonradiographic...
11/06/2023
First Report Managed Care
News
Updated AS and NrxSpA Treatment Recommendations Identify Common Diagnosis Issues, Solutions
10/06/2023
Hannah Musick
Updated evidence-based recommendations were released for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis, including the use of biologics and the role of imaging in patient management.
Updated evidence-based recommendations were released for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis, including the use of biologics and the role of imaging in patient management.
Updated evidence-based...
10/06/2023
First Report Managed Care
News
Baseline MRI and CRP on Treatment Efficacy in NrxSpA
09/27/2023
Danielle Sposato
Over the past decade, biologics have made remarkable advancements in treating axial spondyloarthritis (axSpA). Despite these advances, many patients fail to attain full remission or inactive disease, with only approximately 60% achieving...
Over the past decade, biologics have made remarkable advancements in treating axial spondyloarthritis (axSpA). Despite these advances, many patients fail to attain full remission or inactive disease, with only approximately 60% achieving...
Over the past decade, biologics...
09/27/2023
First Report Managed Care
News
Upadacitinib Benefits Quality of Life and Work Productivity in Adults With NrAxSpA
08/29/2023
Jolynn Tumolo
Explore how Upadacitinib led to rapid and clinically meaningful gains in health-related quality of life and work productivity compared with placebo in patients with nonradiographic axial spondyloarthritis.
Explore how Upadacitinib led to rapid and clinically meaningful gains in health-related quality of life and work productivity compared with placebo in patients with nonradiographic axial spondyloarthritis.
Explore how Upadacitinib led to...
08/29/2023
First Report Managed Care
News
Unfamiliarity With NrAxSpa Can Delay Diagnosis for Years
07/27/2023
Jolynn Tumolo
“Education on cardinal features, epidemiology, burden, and benefits of timely NrAxSpa diagnosis is warranted for health care providers who commonly manage back pain,” researchers advised.
“Education on cardinal features, epidemiology, burden, and benefits of timely NrAxSpa diagnosis is warranted for health care providers who commonly manage back pain,” researchers advised.
“Education on cardinal features,...
07/27/2023
First Report Managed Care
News
Minimal Radiographic Progression Over 2 Years With Secukinumab for NrAxSpa
06/19/2023
Jolynn Tumolo
This study demonstrated minimal radiographic progression and sustained reduction in sacroiliac joint inflammation with secukinumab administered over 2 years for patients with NrAxSpa.
This study demonstrated minimal radiographic progression and sustained reduction in sacroiliac joint inflammation with secukinumab administered over 2 years for patients with NrAxSpa.
This study demonstrated minimal...
06/19/2023
First Report Managed Care
News
One-Fourth of Patients With NrAxSpa Experience No Disease Flare After Stopping Etanercept
05/23/2023
Jolynn Tumolo
Researchers investigate how the current differential diagnosis between radiographic and non-radiographic axial spondyloarthritis affects the prediction of patient outcomes.
Researchers investigate how the current differential diagnosis between radiographic and non-radiographic axial spondyloarthritis affects the prediction of patient outcomes.
Researchers investigate how the...
05/23/2023
First Report Managed Care
News
Continued Golimumab Superior to Withdrawal in Patients With Inactive NrAxSpa
04/21/2023
Jolynn Tumolo
Continued golimumab treatment was superior to withdrawal in preventing disease flares and achieving clinical responses in adults with inactive nonradiographic axial spondyloarthritis.
Continued golimumab treatment was superior to withdrawal in preventing disease flares and achieving clinical responses in adults with inactive nonradiographic axial spondyloarthritis.
Continued golimumab treatment...
04/21/2023
First Report Managed Care
News
Spinal Schwannoma Found in Man With Nonradiographic Axial Spondyloarthritis
03/09/2023
Jolynn Tumolo
A case study detailed the incidence of a rare tumor in a 25-year-old patient with a history of nonradiographic axial spondyloarthritis. 
A case study detailed the incidence of a rare tumor in a 25-year-old patient with a history of nonradiographic axial spondyloarthritis. 
A case study detailed the...
03/09/2023
First Report Managed Care
News
Earlier Treatment May Improve Outcomes in Patients With Nonradiographic Axial Spondyloarthritis
10/14/2022
Jolynn Tumolo
Study authors compared early vs late symptom duration and the efficacy of secukinumab in younger vs older patients with nonradiographic axial spondyloarthritis.
Study authors compared early vs late symptom duration and the efficacy of secukinumab in younger vs older patients with nonradiographic axial spondyloarthritis.
Study authors compared early vs...
10/14/2022
First Report Managed Care

Newsfeed

News
Bimekizumab Demonstrates Rapid and Sustained Efficacy in Treating NrxSpA, Regardless of Prior TNF Inhibitor Exposure
12/21/2023
Hannah Musick
A new monoclonal antibody, bimekizumab (BKZ), demonstrated promising results in improving efficacy outcomes for patients with axial spondyloarthritis (axSpA), even in those who have lost response to TNF inhibitors or are intolerant to them,...
A new monoclonal antibody, bimekizumab (BKZ), demonstrated promising results in improving efficacy outcomes for patients with axial spondyloarthritis (axSpA), even in those who have lost response to TNF inhibitors or are intolerant to them,...
A new monoclonal antibody,...
12/21/2023
First Report Managed Care
News
NrxSpA Classification Holds Little Relevance in Daily Practice
11/06/2023
Jolynn Tumolo
While the terms nonradiographic axial spondyloarthritis (NrxSpA) and radiographic axial spondyloarthritis (R-axSpA) may sometimes be helpful for stratifying patients with axial spondyloarthritis (axSpA) in clinical studies, the terms are less...
While the terms nonradiographic axial spondyloarthritis (NrxSpA) and radiographic axial spondyloarthritis (R-axSpA) may sometimes be helpful for stratifying patients with axial spondyloarthritis (axSpA) in clinical studies, the terms are less...
While the terms nonradiographic...
11/06/2023
First Report Managed Care
News
Updated AS and NrxSpA Treatment Recommendations Identify Common Diagnosis Issues, Solutions
10/06/2023
Hannah Musick
Updated evidence-based recommendations were released for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis, including the use of biologics and the role of imaging in patient management.
Updated evidence-based recommendations were released for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis, including the use of biologics and the role of imaging in patient management.
Updated evidence-based...
10/06/2023
First Report Managed Care
News
Baseline MRI and CRP on Treatment Efficacy in NrxSpA
09/27/2023
Danielle Sposato
Over the past decade, biologics have made remarkable advancements in treating axial spondyloarthritis (axSpA). Despite these advances, many patients fail to attain full remission or inactive disease, with only approximately 60% achieving...
Over the past decade, biologics have made remarkable advancements in treating axial spondyloarthritis (axSpA). Despite these advances, many patients fail to attain full remission or inactive disease, with only approximately 60% achieving...
Over the past decade, biologics...
09/27/2023
First Report Managed Care
News
Upadacitinib Benefits Quality of Life and Work Productivity in Adults With NrAxSpA
08/29/2023
Jolynn Tumolo
Explore how Upadacitinib led to rapid and clinically meaningful gains in health-related quality of life and work productivity compared with placebo in patients with nonradiographic axial spondyloarthritis.
Explore how Upadacitinib led to rapid and clinically meaningful gains in health-related quality of life and work productivity compared with placebo in patients with nonradiographic axial spondyloarthritis.
Explore how Upadacitinib led to...
08/29/2023
First Report Managed Care
News
Unfamiliarity With NrAxSpa Can Delay Diagnosis for Years
07/27/2023
Jolynn Tumolo
“Education on cardinal features, epidemiology, burden, and benefits of timely NrAxSpa diagnosis is warranted for health care providers who commonly manage back pain,” researchers advised.
“Education on cardinal features, epidemiology, burden, and benefits of timely NrAxSpa diagnosis is warranted for health care providers who commonly manage back pain,” researchers advised.
“Education on cardinal features,...
07/27/2023
First Report Managed Care
News
Minimal Radiographic Progression Over 2 Years With Secukinumab for NrAxSpa
06/19/2023
Jolynn Tumolo
This study demonstrated minimal radiographic progression and sustained reduction in sacroiliac joint inflammation with secukinumab administered over 2 years for patients with NrAxSpa.
This study demonstrated minimal radiographic progression and sustained reduction in sacroiliac joint inflammation with secukinumab administered over 2 years for patients with NrAxSpa.
This study demonstrated minimal...
06/19/2023
First Report Managed Care
News
One-Fourth of Patients With NrAxSpa Experience No Disease Flare After Stopping Etanercept
05/23/2023
Jolynn Tumolo
Researchers investigate how the current differential diagnosis between radiographic and non-radiographic axial spondyloarthritis affects the prediction of patient outcomes.
Researchers investigate how the current differential diagnosis between radiographic and non-radiographic axial spondyloarthritis affects the prediction of patient outcomes.
Researchers investigate how the...
05/23/2023
First Report Managed Care
News
Continued Golimumab Superior to Withdrawal in Patients With Inactive NrAxSpa
04/21/2023
Jolynn Tumolo
Continued golimumab treatment was superior to withdrawal in preventing disease flares and achieving clinical responses in adults with inactive nonradiographic axial spondyloarthritis.
Continued golimumab treatment was superior to withdrawal in preventing disease flares and achieving clinical responses in adults with inactive nonradiographic axial spondyloarthritis.
Continued golimumab treatment...
04/21/2023
First Report Managed Care
News
Spinal Schwannoma Found in Man With Nonradiographic Axial Spondyloarthritis
03/09/2023
Jolynn Tumolo
A case study detailed the incidence of a rare tumor in a 25-year-old patient with a history of nonradiographic axial spondyloarthritis. 
A case study detailed the incidence of a rare tumor in a 25-year-old patient with a history of nonradiographic axial spondyloarthritis. 
A case study detailed the...
03/09/2023
First Report Managed Care
Behind the Bill
New Bill Would Expand Medicare and Medicaid Access to Community Health Workers
09/18/2026
Hannah Musick
The Community Health Worker Access Act would expand Medicare reimbursement for community health worker services and incentivize states to broaden Medicaid coverage, potentially strengthening care navigation, preventive support, and...
The Community Health Worker Access Act would expand Medicare reimbursement for community health worker services and incentivize states to broaden Medicaid coverage, potentially strengthening care navigation, preventive support, and...
The Community Health Worker...
09/18/2026
First Report Managed Care
News
US Vitiligo Study Finds Short Treatment Duration, Variable Care Patterns
09/18/2026
Grace Taylor, MS, MA
A study found that US patients with vitiligo showed short treatment durations and highly variable treatment patterns, while approximately one-third received no treatment following diagnosis.
A study found that US patients with vitiligo showed short treatment durations and highly variable treatment patterns, while approximately one-third received no treatment following diagnosis.
A study found that US patients...
09/18/2026
First Report Managed Care
News
GLP-1 Coverage Linked to Higher Utilization and Costs in Employer-Sponsored Health Plans
09/17/2026
Rebecca Amrick
Researchers found that between 2021 and 2024, utilization of glucagon-like peptide-1 (GLP-1) medications increased among patients with obesity, with greater growth among plans providing coverage for GLP-1 drugs.
Researchers found that between 2021 and 2024, utilization of glucagon-like peptide-1 (GLP-1) medications increased among patients with obesity, with greater growth among plans providing coverage for GLP-1 drugs.
Researchers found that between...
09/17/2026
First Report Managed Care
News
Epcoritamab Plus R2 Demonstrates Long-Term Cost-Effectiveness in Relapsed or Refractory FL
09/17/2026
Rebecca Amrick
A cost-effectiveness analysis indicated that adding epcoritamab to lenalidomide plus rituximab (R2) could reduce long-term health care spending for patients with relapsed or refractory follicular lymphoma (FL).
A cost-effectiveness analysis indicated that adding epcoritamab to lenalidomide plus rituximab (R2) could reduce long-term health care spending for patients with relapsed or refractory follicular lymphoma (FL).
A cost-effectiveness analysis...
09/17/2026
First Report Managed Care
News
Fewer PA Requirements Among System-Affiliated MA Health Plans
09/16/2026
Rebecca Amrick
Medicare Advantage (MA) plans affiliated with health systems had fewer prior authorization (PA) requirements than unaffiliated plans, with the largest differences observed for behavioral and mental health services and dialysis.
Medicare Advantage (MA) plans affiliated with health systems had fewer prior authorization (PA) requirements than unaffiliated plans, with the largest differences observed for behavioral and mental health services and dialysis.
Medicare Advantage (MA) plans...
09/16/2026
First Report Managed Care
News
Monitoring Ruxolitinib Responses Could Optimize Treatment for Polycythemia Vera
09/16/2026
Rebecca Amrick
Monitoring spleen and hematologic responses in patients with ruxolitinib-treated polycythemia vera (PV) enabled researchers to develop a prognostic model that may help physicians identify patients at increased risk of poor outcomes.
Monitoring spleen and hematologic responses in patients with ruxolitinib-treated polycythemia vera (PV) enabled researchers to develop a prognostic model that may help physicians identify patients at increased risk of poor outcomes.
Monitoring spleen and...
09/16/2026
First Report Managed Care
News
The Impact of Atopic Comorbidities on Health Care Utilization for Atopic Dermatitis
09/15/2026
Rebecca Amrick
New research suggests an association between atopic comorbidities and health care utilization and costs among young children with atopic dermatitis.
New research suggests an association between atopic comorbidities and health care utilization and costs among young children with atopic dermatitis.
New research suggests an...
09/15/2026
First Report Managed Care
News
Real-World Study Identifies Factors Associated With Successful TKI Discontinuation in CML
09/14/2026
Rebecca Amrick
Among patients with CML who discontinued TKI therapy, sustained deep molecular response, lower Sokal scores, and longer treatment duration were associated with a greater likelihood of maintaining treatment-free remission.
Among patients with CML who discontinued TKI therapy, sustained deep molecular response, lower Sokal scores, and longer treatment duration were associated with a greater likelihood of maintaining treatment-free remission.
Among patients with CML who...
09/14/2026
First Report Managed Care
Behind the Bill
House Panel Weighs Medicare Payment Reform and Health Care Cybersecurity Legislation
09/14/2026
Hannah Musick
A House panel is weighing bipartisan proposals that could reshape Medicare physician payments and strengthen health care cybersecurity, with potential implications for provider reimbursement, value-based care, network stability, and cyber...
A House panel is weighing bipartisan proposals that could reshape Medicare physician payments and strengthen health care cybersecurity, with potential implications for provider reimbursement, value-based care, network stability, and cyber...
A House panel is weighing...
09/14/2026
First Report Managed Care
News
The Cost-Effectiveness of the JAKPOT Prediction Rule for Erythrocytosis
09/11/2026
Rebecca Amrick
Researchers found upfront JAK2 testing to be more cost-effective in US settings than the JAKPOT predication rule when identifying JAK2 mutations among patients with erythrocytosis.
Researchers found upfront JAK2 testing to be more cost-effective in US settings than the JAKPOT predication rule when identifying JAK2 mutations among patients with erythrocytosis.
Researchers found upfront JAK2...
09/11/2026
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use